Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mukesh K. Nyati

Integration of EGFR Inhibitors With Radiochemotherapy

Nature Reviews Cancer

Cancer Research

Oncology

2006

English

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Cancer Biology and Therapy

English

Related publications

Reverse of EGFR Inhibitors Resistance by Co-Delivering EGFR and Integrin Αvβ3 Inhibitors With Nanoparticles in Non-Small Cell Lung Cancer

English

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research

Cancer Research

Oncology

2015

English

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Research in Oncology

2014

English

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

EGFR Inhibitors, MHC Expression and Immune Responses : Can EGFR Inhibitors Be Used as Immune Response Modifiers?

English

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

English

Accelerated Hyperfractionated Radiochemotherapy With Temozolomide Is Equivalent to Normofractionated Radiochemotherapy in a Retrospective Analysis of Patients With Glioblastoma

English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

QSAR Based Model for Discriminating EGFR Inhibitors and Non-Inhibitors Using Random Forest

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mukesh K. Nyati

Integration of EGFR Inhibitors With Radiochemotherapy

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Related publications

Reverse of EGFR Inhibitors Resistance by Co-Delivering EGFR and Integrin Αvβ3 Inhibitors With Nanoparticles in Non-Small Cell Lung Cancer

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

EGFR Inhibitors, MHC Expression and Immune Responses : Can EGFR Inhibitors Be Used as Immune Response Modifiers?

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Accelerated Hyperfractionated Radiochemotherapy With Temozolomide Is Equivalent to Normofractionated Radiochemotherapy in a Retrospective Analysis of Patients With Glioblastoma

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

QSAR Based Model for Discriminating EGFR Inhibitors and Non-Inhibitors Using Random Forest